Immunovant, Inc. (IMVT)

USD 26.25

(-5.95%)

Annual Income Statements

(In USD)
Breakdown 2024 2023 2022 2021 2020 2019
Revenue - - - - - -
Cost of Revenue 231 Thousand 1.32 Million 1.23 Million 998 Thousand 21 Thousand -
Gross Profit -231 Thousand -1.32 Million -1.23 Million -998 Thousand -21 Thousand -
Operating Expenses 282.7 Million 208.27 Million 156.03 Million 108.11 Million 66.07 Million 448.00
Selling, General and Administrative Expenses 57.28 Million 48.01 Million 54.22 Million 39.51 Million 18.15 Million 448.00
Research and Development Expenses 212.92 Million 160.25 Million 101.8 Million 68.6 Million 47.92 Million 25.73 Million
Other Expenses 12.5 Million -253 Thousand -781 Thousand 328 Thousand 412 Thousand -
Cost and Expenses 282.7 Million 208.27 Million 156.03 Million 108.11 Million 66.07 Million 448.00
Operating Income -282.7 Million -198.46 Million -156.15 Million -107.78 Million -65.66 Million -450.00
Interest Expense - 12.48 Million 655 Thousand - 625 Thousand -
Income Tax Expense 567 Thousand 9000.00 -84 Thousand -358 Thousand 97 Thousand 19 Thousand
Earnings before Tax -258.76 Million -210.95 Million -156.81 Million -107.78 Million -66.29 Million -448.00
Net Income -259.33 Million -210.96 Million -156.73 Million -107.43 Million -66.38 Million -448.00
Earnings Per Share Basic -1.88 -1.71 -1.43 -1.22 -1.54 -
Earnings Per Share Diluted -1.88 -1.71 -1.43 -1.22 -1.54 -
Weighted Average Shares Outstanding 138.1 Million 123.07 Million 109.67 Million 87.75 Million 43.19 Million 14.37 Million
Weighted Average Shares Outstanding (Diluted) 138.1 Million 123.07 Million 109.67 Million 87.75 Million 43.19 Million 14.37 Million
Gross Margin - - - - - -
EBIT Margin - - - - - -
Profit Margin - - - - - -
EBITDA -269.97 Million -209.62 Million -155.58 Million -106.79 Million -65.64 Million -28.41 Million
Earnings Before Tax Margin - - - - - -

Income Statement Charts